- Intas to gain commercialization rights for Etanercept biosimilar in more than 150countries worldwide.
- mAbxience to develop, manufacture, and supply the Etanercept biosimilar.
- This collaboration marks a significant step forward in providing enhanced global access to advanced treatments for autoimmune diseases.
MADRID, Spain I December 20, 2023 I mAbxience (a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma) has announced today a strategic licensing agreement with Intas Pharmaceuticals Ltd, a leading multinational pharmaceutical company. Under this collaboration, Intas will hold the rights to commercialize Etanercept through its affiliates for the treatment of various autoimmune diseases, in more than 150 countries across the globe, including Europe and the United States of America.
This new agreement signifies mAbxience’s commitment to addressing the pressing need for innovative and affordable treatment options for autoimmune diseases. mAbxience will oversee the development, manufacturing, and supply of this groundbreaking biosimilar from its state-of-the-art, Good Manufacturing Practices (GMP)-approved facilities.
“Expanding our global reach has always been at the core of mAbxience’s vision. Collaborating with Intas allows us to tap into new markets and bring our cutting-edge biosimilar candidate to countless patients battling autoimmune diseases. It reinforces our dedication to leading the way in the biosimilar industry,” said Jurgen Van Broeck, Global Commercial Director, mAbxience.
“Partnering up with mAbxience, who are known for their dedication to quality and innovation, aligns perfectly with our vision. This partnership enables us to achieve our goal of providing high-quality treatments to patients worldwide. Together, we aim to revolutionize the landscape of autoimmune disease treatment.” Said Intas’ Vice Chairman, Mr. Binish Chudgar.
Paul Tredwell, Executive Vice President of EMENA., Accord, said “Accord is delighted to partner with mAbxience, whom we have known for some time as an excellent partner. This partnership cements our commitment to our autoimmune franchise, building on our innovative range of methotrexate products, Etanercept is a key biologic treatment which will continue to support patients. This, along with our future biological launches significantly increases our presence in our growing autoimmune franchise.”
The economic terms of this licensing agreement remain confidential. This global collaboration not only fortifies mAbxience’s position as a leader in the biosimilar industry but also showcases the power of joint efforts in the pharmaceutical world to enhance global health outcomes.
This announcement follows a series of successful collaborations mAbxience has engaged in, reinforcing the Company’s commitment to advancing healthcare solutions globally. With this new partnership, mAbxience and Intas are poised to make a lasting impact on the lives of millions affected by autoimmune diseases.
About INTAS
Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India, having end-to-end capabilities of formulation development, manufacturing, and marketing along with backward integration of APIs. Intas also has strong in-house Biosimilar development and marketing capabilities with more than 15 products being marketed. Intas has more than 19,000 employees, with presence in 85 countries and has 14 manufacturing sites worldwide. The Intas group’s revenues amounted to 2.5 BN USD and the compounded annual growth rate of Intas’ revenues has exceeded 25% in the past 10 years.
About mAbxience:
mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. In August 2022, Fresenius Kabi and Insud Pharma entered into an agreement whereby Fresenius Kabi acquired a majority stake of mAbxience, making it a global, vertically integrated fully-fledged biotechnology company. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in development, we have established a B2B presence in over 100 markets. Alongside this, we have formed a network with more than 30 partners and built a dedicated team of over 1,000 professionals. Our three multi-product facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA, and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization services (CDMO), utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions. For more insights into mAbxience, our biosimilars and CDMO business, please visit our website (www.mabxience.com) or connect with us on LinkedIn.
SOURCE: mAbxience
Post Views: 357
- Intas to gain commercialization rights for Etanercept biosimilar in more than 150countries worldwide.
- mAbxience to develop, manufacture, and supply the Etanercept biosimilar.
- This collaboration marks a significant step forward in providing enhanced global access to advanced treatments for autoimmune diseases.
MADRID, Spain I December 20, 2023 I mAbxience (a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma) has announced today a strategic licensing agreement with Intas Pharmaceuticals Ltd, a leading multinational pharmaceutical company. Under this collaboration, Intas will hold the rights to commercialize Etanercept through its affiliates for the treatment of various autoimmune diseases, in more than 150 countries across the globe, including Europe and the United States of America.
This new agreement signifies mAbxience’s commitment to addressing the pressing need for innovative and affordable treatment options for autoimmune diseases. mAbxience will oversee the development, manufacturing, and supply of this groundbreaking biosimilar from its state-of-the-art, Good Manufacturing Practices (GMP)-approved facilities.
“Expanding our global reach has always been at the core of mAbxience’s vision. Collaborating with Intas allows us to tap into new markets and bring our cutting-edge biosimilar candidate to countless patients battling autoimmune diseases. It reinforces our dedication to leading the way in the biosimilar industry,” said Jurgen Van Broeck, Global Commercial Director, mAbxience.
“Partnering up with mAbxience, who are known for their dedication to quality and innovation, aligns perfectly with our vision. This partnership enables us to achieve our goal of providing high-quality treatments to patients worldwide. Together, we aim to revolutionize the landscape of autoimmune disease treatment.” Said Intas’ Vice Chairman, Mr. Binish Chudgar.
Paul Tredwell, Executive Vice President of EMENA., Accord, said “Accord is delighted to partner with mAbxience, whom we have known for some time as an excellent partner. This partnership cements our commitment to our autoimmune franchise, building on our innovative range of methotrexate products, Etanercept is a key biologic treatment which will continue to support patients. This, along with our future biological launches significantly increases our presence in our growing autoimmune franchise.”
The economic terms of this licensing agreement remain confidential. This global collaboration not only fortifies mAbxience’s position as a leader in the biosimilar industry but also showcases the power of joint efforts in the pharmaceutical world to enhance global health outcomes.
This announcement follows a series of successful collaborations mAbxience has engaged in, reinforcing the Company’s commitment to advancing healthcare solutions globally. With this new partnership, mAbxience and Intas are poised to make a lasting impact on the lives of millions affected by autoimmune diseases.
About INTAS
Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India, having end-to-end capabilities of formulation development, manufacturing, and marketing along with backward integration of APIs. Intas also has strong in-house Biosimilar development and marketing capabilities with more than 15 products being marketed. Intas has more than 19,000 employees, with presence in 85 countries and has 14 manufacturing sites worldwide. The Intas group’s revenues amounted to 2.5 BN USD and the compounded annual growth rate of Intas’ revenues has exceeded 25% in the past 10 years.
About mAbxience:
mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. In August 2022, Fresenius Kabi and Insud Pharma entered into an agreement whereby Fresenius Kabi acquired a majority stake of mAbxience, making it a global, vertically integrated fully-fledged biotechnology company. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in development, we have established a B2B presence in over 100 markets. Alongside this, we have formed a network with more than 30 partners and built a dedicated team of over 1,000 professionals. Our three multi-product facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA, and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization services (CDMO), utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions. For more insights into mAbxience, our biosimilars and CDMO business, please visit our website (www.mabxience.com) or connect with us on LinkedIn.
SOURCE: mAbxience
Post Views: 357
